Floatz logo

Indobufen

Indobufen

Beijing Tiantan HospitalSmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Indobufen cohort.

Asset / SponsorPhaseRating
Acetylsalicylic Acid
Beijing Tiantan Hospital
Phase 4BB

Same molecule, other indications

Indobufen is also rated in:

AspirinDormant
BB
Indicative ·
69 / 100
View asset →
ischemic strokeDormant
B
Indicative ·
58 / 100
View asset →
Vertebral Artery StenosisDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →